| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Medtronic (NYSE:MDT) has been trapped in a tight consolidation band for what feels like forever. For more than 1,100 days, the stock has stubbornly stayed between $75 and $95, showing little sign of life. While this may seem like random sideways action, a closer look through the lens of the Adhishthana Principles brings clarity to why the stock has underperformed and what may lie ahead.
Within the Adhishthana framework, Phases 14, 15, and 16 form what are known as the Guna Triads. These are pivotal in shaping whether a stock can achieve Nirvana in Phase 18, the culmination of the cycle. For that to happen, the triads must display Satoguna, which represents a clean and sustainable bullish structure.
As outlined in Adhishthana: The Principles That Govern Wealth, Time & Tragedy:
"Without noticeable Satoguna in any of the triads, no Nirvana can emerge in Phase 18."
In Medtronic's case, the triads unfolded without any convincing bullish momentum, leaving Phase 18 without the fuel for a Nirvana rally. That explains the long grind of underperformance. Since entering its weekly Phase 18, the stock has essentially been boxed into a range, offering little for trend-following investors.
This lack of movement is not just short-term noise. The current consolidation is expected to persist until late November this year, when Phase 18 finally comes to a close.
Medtronic is a case study in how weak triads ripple into prolonged stagnation. With both the weekly and monthly charts locked in Phase 18, the structure suggests that the stock will remain stuck without any meaningful bullish breakout.
For investors, that means patience or avoidance. Until November's cycle shift brings fresh clarity, Medtronic is unlikely to reward long-term holders. Traders may attempt to play the range, but for most, stepping aside may be the wiser call.
Also read our analysis of Jack Henry & Associates (NASDAQ:JKHY), which is exhibiting a similar pattern here.
Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.
